| Primary |
| Hyperphosphataemia |
42.0% |
| Product Used For Unknown Indication |
37.2% |
| Renal Failure Chronic |
5.4% |
| Hypertension |
3.8% |
| Hyperparathyroidism Secondary |
1.6% |
| Diabetes Mellitus |
1.3% |
| Drug Use For Unknown Indication |
1.2% |
| Constipation |
1.0% |
| Insomnia |
0.8% |
| Angina Pectoris |
0.7% |
| Pruritus |
0.7% |
| Vitamin Supplementation |
0.6% |
| Blood Cholesterol Increased |
0.6% |
| Hyperuricaemia |
0.6% |
| Atrial Fibrillation |
0.5% |
| Cardiac Disorder |
0.5% |
| Dialysis |
0.5% |
| Hiv Infection |
0.5% |
| Renal Failure |
0.5% |
| Gastritis |
0.4% |
|
| Death |
34.8% |
| Vomiting |
8.2% |
| Wrong Technique In Drug Usage Process |
8.2% |
| X-ray Abnormal |
7.8% |
| Ileus |
4.9% |
| Myocardial Infarction |
4.4% |
| Hospitalisation |
3.8% |
| Intestinal Obstruction |
3.4% |
| Cardiac Arrest |
2.8% |
| Sepsis |
2.5% |
| Pneumonia |
2.4% |
| Nausea |
2.3% |
| Peritonitis |
2.1% |
| Unevaluable Event |
2.0% |
| Constipation |
1.8% |
| Overdose |
1.8% |
| Pancreatitis |
1.8% |
| Gastrointestinal Haemorrhage |
1.7% |
| Rash |
1.7% |
| Diarrhoea |
1.6% |
|
| Secondary |
| Product Used For Unknown Indication |
44.0% |
| Hyperphosphataemia |
22.9% |
| Renal Failure Chronic |
6.4% |
| Hyperparathyroidism Secondary |
6.3% |
| Hypertension |
3.8% |
| Drug Use For Unknown Indication |
3.5% |
| Myocardial Infarction |
2.2% |
| Haemorrhage Prophylaxis |
1.5% |
| Gastritis |
1.2% |
| Pruritus |
1.2% |
| Diabetes Mellitus |
1.0% |
| Constipation |
0.9% |
| Hyperkalaemia |
0.9% |
| Blood Pressure Increased |
0.7% |
| Insomnia |
0.7% |
| Hiv Infection |
0.6% |
| Pain |
0.6% |
| Atrial Fibrillation |
0.5% |
| Cardiac Disorder |
0.5% |
| Vitamin Supplementation |
0.5% |
|
| Death |
30.1% |
| Ileus |
10.8% |
| Intestinal Obstruction |
6.5% |
| Wrong Technique In Drug Usage Process |
5.4% |
| Gynaecomastia |
4.3% |
| Lumbar Spinal Stenosis |
4.3% |
| Overdose |
4.3% |
| Procedural Hypotension |
4.3% |
| Gastric Ulcer |
3.2% |
| Myocardial Infarction |
3.2% |
| Subileus |
3.2% |
| Gastrointestinal Perforation |
2.7% |
| Hypocalcaemia |
2.7% |
| X-ray Gastrointestinal Tract Abnormal |
2.7% |
| Encephalopathy |
2.2% |
| Gastrointestinal Disorder |
2.2% |
| Prescribed Overdose |
2.2% |
| Pruritus |
2.2% |
| Sepsis |
2.2% |
| Ataxia |
1.6% |
|
| Concomitant |
| Product Used For Unknown Indication |
37.4% |
| Drug Use For Unknown Indication |
25.6% |
| Nuclear Magnetic Resonance Imaging |
7.6% |
| Hypertension |
4.9% |
| Hyperparathyroidism Secondary |
3.0% |
| Angiogram |
3.0% |
| Renal Failure Chronic |
2.4% |
| Peritoneal Dialysis |
2.2% |
| Hyperphosphataemia |
2.0% |
| Dialysis |
1.5% |
| Nephrogenic Anaemia |
1.4% |
| Pain |
1.4% |
| Hyperparathyroidism |
1.2% |
| Anaemia |
1.0% |
| Prophylaxis |
1.0% |
| Fistulogram |
0.9% |
| Nuclear Magnetic Resonance Imaging Brain |
0.9% |
| Thrombosis Prophylaxis |
0.8% |
| Diabetes Mellitus |
0.8% |
| Haemodialysis |
0.8% |
|
| Vomiting |
20.0% |
| Skin Tightness |
10.1% |
| Thrombocytopenia |
7.5% |
| Nephrogenic Systemic Fibrosis |
5.7% |
| Therapeutic Response Decreased |
5.4% |
| Transaminases Increased |
5.4% |
| Unresponsive To Stimuli |
4.2% |
| Nausea |
3.9% |
| Aplasia Pure Red Cell |
3.6% |
| Drug Ineffective |
3.3% |
| Peritonitis Bacterial |
3.3% |
| Skin Induration |
3.3% |
| Swelling |
3.3% |
| Xerosis |
3.3% |
| Death |
3.0% |
| Hypoglycaemia |
3.0% |
| Myocardial Infarction |
3.0% |
| Peritonitis |
3.0% |
| Sepsis |
3.0% |
| Weight Decreased |
3.0% |
|
| Interacting |
| Hiv Infection |
42.9% |
| Hypertension |
28.6% |
| Hyperphosphataemia |
14.3% |
| Renal Failure |
14.3% |
|
|
